Loading
Life sciences · Journal article
Frontiers in Tropical Diseases · October 9, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Dermatophytosis affects approximately 25% of the world population. Terbinafine, an antifungal medication, was historically used to treat this condition. However, the infection caused by a newer fungal species called Trichophyton indotineae has changed this situation, as it responds poorly to terbinafine. Moreover, the infection caused by this species lasts longer, returns repeatedly after treatment, and can spread over large areas of the body. This fungus was first linked to major recurrent and chronic skin infections in India and has now spread across the globe having been identified in Asia, the Middle East, Europe, and North America. The major concern is that this infection, caused by T. indotineae, may be spreading internationally, and carrying antifungal resistance, it could pose a serious global public health problem. This review discusses five main aspects of T. indotineae: taxonomic classification, epidemiology, mechanism of drug resistance, diagnostic limitations, and management challenges leading to treatment failure. The mechanism of action of terbinafine is to bind and block the fungal enzyme squalene epoxidase, which is required to produce ergosterol, a component of the cell membrane. In resistant strains, point mutations occur in the squalene epoxidase gene, particularly Leu393Phe and Phe397Leu, changing the structure of the enzyme, and terbinafine cannot bind effectively, leading to treatment failure and recurrence. Resistance to alternative drugs like itraconazole and other azoles is also increasing through the overexpression of efflux pumps. In addition, several clinical and public health problems, such as the increasing use of over-the-counter corticosteroid creams, species identification delays, household transmission, and limited public health surveillance, have also contributed to the spread and resistance of this fungal infection. There are several knowledge gaps. Addressing this threat by T. indotineae requires standardised laboratories with genetic testing to identify the species; treatment guided by susceptibility; antifungal stewardship that selects the appropriate antifungal drug, dose, and treatment duration; regulation of the use of combination drugs; international surveillance; and high-quality, multicentre RCTs to establish evidence-based dosing regimens.